You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR MONISTAT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for MONISTAT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01661556 ↗ Clinical Trial of Hydroquinone Versus Miconazol in Melasma Unknown status Hospital Central "Dr. Ignacio Morones Prieto" Phase 4 2011-10-01 Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%), and the other group topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 30. The purpose of this study is determine if there is a difference in the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded.
NCT01661556 ↗ Clinical Trial of Hydroquinone Versus Miconazol in Melasma Unknown status Universidad Autonoma de San Luis Potosí Phase 4 2011-10-01 Melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.The duration of this double-blind clinical trial will be 12 weeks. The control group will receive treatment with topical Hydroquinone (4%), and the other group topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for melasma patients. The estimated number of subjects to be recruited and randomized for the study is at least 30. The purpose of this study is determine if there is a difference in the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry and histological assessment will be also evaluated. Occurrence of adverse effects will also be recorded.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MONISTAT

Condition Name

Condition Name for MONISTAT
Intervention Trials
Melasma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for MONISTAT
Intervention Trials
Melanosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for MONISTAT

Trials by Country

Trials by Country for MONISTAT
Location Trials
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for MONISTAT

Clinical Trial Phase

Clinical Trial Phase for MONISTAT
Clinical Trial Phase Trials
Phase 4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for MONISTAT
Clinical Trial Phase Trials
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MONISTAT

Sponsor Name

Sponsor Name for MONISTAT
Sponsor Trials
Hospital Central "Dr. Ignacio Morones Prieto" 1
Universidad Autonoma de San Luis Potosí 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for MONISTAT
Sponsor Trials
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.